Consensus NeoGenomics, Inc.

Equities

NEO

US64049M2098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.14 ^USD	+2.09%		+4.51%	-12.61%

Apr. 18	NeoGenomics, Inc. Announces Senior Leadership Promotions	CI
Apr. 18	NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics	CI

Evolution of the average Target Price on NeoGenomics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b278ed2a66d7456fb9f5a01f9bbe386.HvhMlALKCIfCzQIvka7YpIf7QXrx_-OCNOqbSQd6JH8.bJMi7m77fu6R9UdjyMqy1OCqLxGji4TueoCqCmEIXB5SkyS5db5MqpKXNg~21c85283b9ea21f5815951f894f43e23

Analyst Recommendations on NeoGenomics, Inc.

Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating	Feb. 26	MT
Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating	Feb. 22	MT
Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating	Feb. 21	MT
TD Cowen Cuts Price Target on NeoGenomics to $19 From $22, Maintains Outperform Rating	Dec. 29	MT
BTIG Cuts Price Target on NeoGenomics to $21 From $25, Keeps Buy Rating	Dec. 29	MT
Morgan Stanley Cuts Price Target on NeoGenomics to $16 From $18, Maintains Equal-Weight Rating	23-10-24	MT
Goldman Sachs Cuts Price Target on NeoGenomics to $17 From $19, Maintains Buy Rating	23-10-23	MT
BofA Securities Adjusts Price Target on NeoGenomics to $15 From $17, Maintains Neutral Rating	23-10-20	MT
Stephens Upgrades NeoGenomics to Overweight From Equal-Weight, Price Target at $18	23-08-21	MT
TD Cowen Adjusts Price Target on NeoGenomics to $23 From $22, Maintains Outperform Rating	23-08-09	MT
Benchmark Trims Price Target on NeoGenomics to $18 From $20, Maintains Buy Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $18 From $19, Maintains Equal-Weight Rating	23-08-09	MT
Raymond James Downgrades NeoGenomics to Market Perform From Outperform	23-05-16	MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $19 From $18, Maintains Equal-Weight Rating	23-05-10	MT
BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $25	23-05-09	MT
TD Cowen Adjusts Price Target on NeoGenomics to $22 From $20, Maintains Outperform Rating	23-05-09	MT
BofA Adjusts Price Target on NeoGenomics to $17 From $18, Keeps Neutral Rating	23-04-11	MT
Piper Sandler Adjusts NeoGenomics' Price Target to $20 From $18, Keeps Overweight Rating	23-03-03	MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $18 From $17, Maintains Equal-Weight Rating	23-02-24	MT
Raymond James Raises Price Target on NeoGenomics to $19 From $12, Maintains Outperform Rating	23-02-24	MT
Needham Increases Price Target on NeoGenomics to $21 From $15, Maintains Buy Rating	23-02-24	MT
Benchmark Upgrades NeoGenomics to Buy From Hold, Price Target is $20	23-02-24	MT
Needham Upgrades NeoGenomics to Buy From Hold, Price Target is $15	23-02-01	MT
Piper Sandler Adjusts Price Target on NeoGenomics to $18 From $19, Maintains Overweight Rating	22-11-14	MT
Raymond James Adjusts Price Target on NeoGenomics to $12 From $15, Maintains Outperform Rating	22-11-11	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.14 USD

Average target price

21.1 USD

Spread / Average Target

+49.22%

High Price Target

30 USD

Spread / Highest target

+112.16%

Low Price Target

18 USD

Spread / Lowest Target

+27.30%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeoGenomics, Inc.

Piper Sandler
Goldman Sachs
Needham & Co.
TD Cowen
BTIG
Morgan Stanley
BofA Securities
Stephens Inc.
Benchmark Company
Raymond James
SVB Securities LLC
SVB Leerink
Benchmark Capital
Cowen
Truist Securities

Ratings for NeoGenomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar